EQS-News

Alzchem Group AG seamlessly builds on strong business performance in 2023 with EBITDA growth of 31.7% in first quarter 2024

EQS-News: Alzchem Group AG / Key word(s): Quarterly / Interim Statement Alzchem Group AG seamlessly builds on strong business performance in 2023 with EBITDA growth of 31.7% in first quarter 2024 30.04.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Alzchem Group AG seamlessly builds on strong business performance in 2023 with EBITDA growth of 31.7% in first quarter 2024

• Result for the period increases significantly by 58.7% to EUR 12.2 million
• Strong free cash flow of EUR 26.6 million
• Management Board confirms forecasts for the full year 2024

Trostberg, April 30, 2024 – Alzchem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, reports a successful start to the fiscal year 2024. With consolidated sales of EUR 150.1 million in the first quarter, the company was able to confirm the previous year’s strong level of EUR 150.4 million. As in the full year 2023, the Specialty Chemicals business proved to be a key success factor, achieving significant growth in both sales (+8.4%) and EBITDA (+41.6%). The Specialty Chemicals growth segment thus successfully compensated for the expected decline in sales and EBITDA (-14.0% and -35.2% respectively) in the Basics & Intermediates segment. The Human Nutrition (Creapure), Animal Nutrition (Creamino) and Defense ((nitroguanidine) divisions in particular performed strongly in the first three months of 2024. By contrast, business in the Custom Manufacturing segment (multi-purpose plants), which is significantly influenced by the general economic situation in the chemical industry, and in nitriles, due to persistently strong competition from Asia, remained challenging.

The strategic optimization of the product mix towards higher-margin specialty chemicals is impressively reflected in the earnings performance in the first quarter of 2024. At EUR 24.9 million, Alzchem was able to increase Group EBITDA by 31.7 % (previous year: EUR 18.9 million). Based on the stable sales development, the EBITDA margin increased from 12.6% to 16.6%. The result for the period climbed by 58.7% quarter-on-quarter from EUR 7.7 million to EUR 12.2 million. The scaling of plant expansions, particularly in the Human Nutrition division, had a very positive effect on earnings. The Animal Nutrition and Defense divisions also made important contributions to earnings. In addition, the fact that the manufacturing costs of products in the Specialty Chemicals segment are significantly less affected by the price of electricity than in the Basics & Intermediates segment also has a generally positive effect on earnings. In the reporting period, electricity prices allowed price reductions for customers, particularly in the more electricity-intensive Basics & Intermediates segment, although this is reflected in the lower sales of this segment.